Naratriptan

Naratriptan
Clinical data
Trade names	Amerge, Naramig, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601083
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral
ATC code	N02CC02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	74%
Metabolism	Hepatic
Elimination half-life	5-8 hours
Excretion	Renal
Identifiers
	IUPAC name N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;
CAS Number	121679-13-8 ;
PubChem CID	4440;
IUPHAR/BPS	45;
DrugBank	DB00952 ;
ChemSpider	4287 ;
UNII	QX3KXL1ZA2;
KEGG	D08255 ;
ChEBI	CHEBI:7478 ;
ChEMBL	ChEMBL1278 ;
CompTox Dashboard (EPA)	DTXSID7023354 ;
ECHA InfoCard	100.121.501
Chemical and physical data
Formula	C17H25N3O2S
Molar mass	335.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(NC)CCc3ccc1c(c(c[nH]1)C2CCN(C)CC2)c3;
	InChI InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3 ; Key:AMKVXSZCKVJAGH-UHFFFAOYSA-N ;
	(verify)

Naratriptan (trade names include Amerge) is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It is a selective 5-HT₁ receptor subtype agonist.

It was patented in 1987 and approved for medical use in 1997.^[1]

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 978-3-527-60749-5.